Rheumnow Podcast

Επεισόδια

• 
  Doubting RS3PE (8.14.2026) 14.08.2026 31λ

  Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
• 
  Mentshlichkeit (8.7.2026) 07.08.2026 22λ

  Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com
• 
  A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12 03.08.2026 25λ

  Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026. Learn how those findings impact their clinical decision-making. Sponsored by AbbVie Medical Affairs + Health Impact
• 
  TU: Systemic Burden of Gout Part 2 (24 plus) 31.07.2026 29λ

  Dr. Jack Cush Obesity & Gout Dr. Tony Merriman Genome-Wide Association Studies in Gout Dr. Lisa Stamp Gout Management in Patients with Chronic Kidney Disease Dr. Mark Fisher Gout & Mortality  
• 
  Methotrexate Safety Tips (7.31.2026) 31.07.2026 20λ

  Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
• 
  Gout Lessons from the Clinic Part 3 30.07.2026 28λ

  Dr. Sheila Reyes: QD Clinic: The Highs and Lows of a Woman with Gout Dr. Jack Cush QD319 A Watched Tophus Never Resolves  Dr. Eric Dein QD316: Addressing Severe Gout Flares  Dr. Janet Pope QD Clinic: RA Mimics — Two Cases That Turned Out to Be Gout 
• 
  DERM on RheumNow (July 2026) 29.07.2026 10λ

  The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com.Show Notes: - 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72 Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21 Guidelines to Spot Cancer in High Risk Dermatomyositis Psoriatic Arthritis: EULAR 2026
• 
  New, Advanced Therapies in Gout 29.07.2026 1ώ 1λ

  New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)
• 
  Systemic Burden of Gout Part 1 29.07.2026 34λ

  Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology Dr. Nicola Dalbeth Outcomes of Tophaceous Gout  Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?
• 
  Better Gout Management 29.07.2026 19λ

  Dr. John Fitzgerald Gout & Metabolic syndrome Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity
• 
  Gout Advice & Tips 29.07.2026 24λ

  Dr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome  Dr. Angelo Gaffo Challenges in Gout Diagnosis Dr. Janet Pope Tips for safe use of allopurinol in patients with gout
• 
  Gout Lessons from the Clinic Part 2 29.07.2026 30λ

  Dr Janet Pope: QD Clinic: Can RA and Gout Manifest Simultaneously? Dr. Mrinalini Dey QD312: Gout, Sepsis… or Both? Daric Mueller, PA-C QD315: Pegloticase Immunomodulation: What’s on the Menu? Dr. Richard Conway: QD313: Don't Presume on IL-1 in Gout 
• 
  Chikungunya Club Meeting (7.24.2026) 24.07.2026 29λ

  Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com
• 
  Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) 22.07.2026 1ώ 5λ

  Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo  Dr. Lisa Stamp  Dr. Michael Pillinger  Dr. Ted Mikuls  Moderator: Dr. Jack Cush
• 
  Seronegative RA Disease Activity (7.17.2026) 17.07.2026 21λ

  Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com
• 
  What Lies Beneath - Uric Acid Deposition & Imaging 15.07.2026 59λ

  This webinar explores the evolving role of imaging in the diagnosis and management of gout. Our expert panel will discuss when and how to use ultrasound, dual-energy CT (DECT), crystal identification, and conventional radiography, while addressing practical questions such as the role of imaging in diagnostic uncertainty, serial disease monitoring, and whether ultrasound is changing the need for synovial fluid analysis in everyday practice. Panelists: Dr. Nicola Dalbeth Dr. John Fitzgerald Dr. Sarah Tedeschi Dr. Jack Cush (moderator)
• 
  Gout QD clinics - lessons from the Clinic QD307-QD311 13.07.2026 38λ

  QD307: Senior Year Gout   https://youtu.be/_TGgcdQsficQD308: Allopurinol for All Gout? Not Quite  https://youtu.be/JAwUb-hqeFsQD309: Cellulitis Paradoxes  https://youtu.be/j3feySk5wQoQD310: Gout: Is it the Journey or the Destination? https://youtu.be/1J-ZrbaGsD8QD311: When There's Doubt in Gout  https://youtu.be/DpAevfq7Oo0
• 
  Gout Cavalcade (7.10.2026) 10.07.2026 27λ

  Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month. Visit https://rheumnow.com/campaign/gout-campaign-july-2026 for all of our coverage throughout July.
• 
  Gout Journal Club 08.07.2026 57λ

  Gout Journal Club will examine two influential publications: 1. "Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients with Gout" (Cipolletta et al., JAMA Internal Medicine, 2026) and 2. "Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease"(Wang et al., JAMA Internal Medicine, 2025). Together, these studies provide new evidence supporting treat-to-target urate-lowering strategies and their potential impact on cardiovascular and renal outcomes. Panelists: Abhishek Abhishek, MD, PhD, MBBS, FRCP Zeqin Wen, MD Jie Wei, PhD Jack Cush, MD (moderator) Beyond reviewing the evidence, our expert panel will tackle the practical questions rheumatologists face every day.
• 
  Podcast Replay: Is it Time to Transition MOAs in RA? 07.07.2026 17λ

  In August, Dr. Christina Charles-Schoeman and Dr. Manish Jain will return with a new episode exploring the latest clinical data on RA treatment after TNFi failure. Before that episode drops, revisit their 2025 conversation on disease control, real-world data, and guidelines that inform clinical decision-making after TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact.